Skip to content
AnalystLens

IDEXX Laboratories 8-K Report, Financial Results (Feb 3, 2025)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed February 3, 2025
Period End
February 3, 2025
Security
IDXX
In the record · 2016–202610-K1110-Q338-K98

IDXX filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 98 current reports (8-K) between 2016 and 2026.

  1. Leadership change8-K · Oct ’19Oct ’19
  2. Material agreement8-K · Dec ’21Dec ’21
  3. Leadership change8-K · Mar ’26Mar ’26

Summary

Summary of the 8-K filed February 3, 2025. Cited figures are marked; the original filing is the authoritative source.

IDEXX Laboratories reported fourth quarter 2024 revenue of $954 milliona, up 6% both as reported and organically, led by Companion Animal Group (CAG) growth of 6%.

CAG Diagnostics recurring revenue grew 6% reported and 7% organically, with IDEXX VetLab consumables up 12%. Q4 EPS was $2.62b, up 13% as reported and 10% on a comparable basis, and operating margin expanded 20 basis points as reported (50 bps comparable). Full-year 2024 revenue reached $3,898 million (up 6%), but full-year reported EPS grew only 6% to $10.67 because of a $0.56 per-share charge from a discrete litigation accrual recorded in Q2 2024.

Reported operating margin contracted 100 bps to 29.0%, though comparable margin expanded 60 bps. For 2025, IDEXX guided to revenue of $4,055 million to $4,170 millionc (4% to 7% reported, 6% to 9% organic) and EPS of $11.74 to $12.24 (10% to 15% reported, 8% to 12% comparable). Management targets 200 to 250 bps of reported operating margin improvement, including roughly 160 bps from lapping the 2024 litigation expense.

Guidance assumes about $1.5 billiond in share repurchases in 2025, equal to roughly 4% of current market capitalization, and a 2% to 3% reduction in average shares outstanding. Foreign currency is expected to reduce 2025 revenue growth by about 2 percentage points and EPS by about $0.21. The company also highlighted new product launches, including the IDEXX inVue Dx Cellular Analyzer, which began shipping in Q4 2024, and IDEXX Cancer Dx canine lymphoma screening, planned for late March 2025 in the U.S. and Canada.

Cash flow remained strong, with 2024 free cash flow of $808 million, but cash fell to $288 million at year-end after $837 million of share repurchases. Investors will likely focus on whether the new products can sustain CAG Diagnostics recurring revenue growth, whether the margin recovery holds, and how the aggressive buyback program affects per-share value.

Key Highlights

  1. Q4 2024 revenue of $954 million grew 6% as reported and organically; CAG Diagnostics recurring revenue grew 6% reported and 7% organically.
  2. Q4 EPS of $2.62 rose 13% as reported and 10% comparable; the quarter included a $0.06 non-recurring tax reserve release.
  3. Full-year 2024 reported EPS grew only 6% to $10.67 due to a $0.56 per-share litigation accrual ($61.5 million) in Q2; comparable EPS grew 12%.
  4. 2025 guidance: revenue of $4,055M-$4,170M (4%-7% reported, 6%-9% organic) and EPS of $11.74-$12.24 (10%-15% reported).
  5. Planned ~$1.5 billion of 2025 share repurchases (about 4% of market cap) and a 2%-3% reduction in average shares outstanding.
  6. Foreign currency is a headwind of roughly 2 points to 2025 revenue growth and about $0.21 to EPS.
  7. Year-end cash fell to $288 million after $837 million of 2024 buybacks, and the company carries about $868 million of total debt including the credit facility.

Frequently Asked Questions

  1. What drove IDEXX's fourth quarter 2024 performance?

    Growth was driven by CAG Diagnostics recurring revenue, which rose 6% reported and 7% organically. IDEXX VetLab consumables grew 12%, supported by premium instrument installed base growth (up 9%) and net price gains. Operating margin rose 20 bps as reported (50 bps comparable), and gross margin expanded 140 bps to 59.8%.

  2. Why did reported full-year 2024 EPS grow much less than comparable EPS?

    The company recorded a $61.5 million discrete litigation expense accrual in Q2 2024, which reduced EPS by $0.56. The litigation matter involves alleged underpayment of royalties from 2004 through 2017 under an expired patent license, and the total accrual is now $89.0 million. Excluding this charge, EPS growth was 12% on a comparable basis, though this one-time charge will lap in 2025 and provides a roughly 160 bps margin tailwind.

  3. What does the 2025 guidance imply for investors?

    Guidance calls for 4%-7% reported revenue growth and 10%-15% reported EPS growth. Operating margin is projected at 31.0%-31.5%, and free cash flow is expected at 85%-90% of net income. Foreign currency is a headwind, and the company explicitly states that these estimates are forward-looking and subject to risks described in its 10-K and 10-Q filings.

  4. How will the large share repurchase program affect shareholders?

    Management plans roughly $1.5 billion of buybacks in 2025, which is about 4% of current market capitalization, and expects average shares outstanding to fall 2%-3%. This reduction contributes meaningfully to projected EPS growth, but buybacks depend on market conditions and cut into the cash balance, which was $288 million at year-end 2024.

  5. What are the key product catalysts for IDEXX?

    IDEXX began shipping the inVue Dx Cellular Analyzer, a slide-free cellular analyzer, in Q4 2024. It also plans to launch IDEXX Cancer Dx canine lymphoma screening in late March 2025 in the U.S. and Canada. Management expects these innovations to help drive future instrument placements, recurring revenue, and veterinary workflow efficiency.